Cytokinetics EVP Sells 15,000 Shares at $60.28, Trims Stake
Cytokinetics EVP Andrew Callos sold 15,000 shares at $60.28 on January 5, 2026, trimming his stake to 50,440 shares. He also disposed of 53,528 shares at $65.95–65.96 in December for about $3.46 million, as CYTK trades around $61.26 with a $7.29 billion market cap.
1. Insider Trading Activity Observed in Cytokinetics Executive Vice President
On January 5, 2026, Andrew Callos, Executive Vice President of Cytokinetics, sold 15,000 CYTK shares, trimming his stake to 50,440 shares. This follows December transactions in which he offloaded 1,042 shares on December 8 and 52,486 shares on December 5, cumulatively netting approximately $3.46 million. These moves were disclosed in SEC filings and underscore heightened insider liquidity during a period when the stock has rallied from its yearly low to recent levels, contributing to trading volumes exceeding two million shares daily. Investors are closely watching whether this activity signals shifting confidence in the company’s near-term catalysts.
2. Cytokinetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Cytokinetics President and CEO Robert I. Blum will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM Pacific Time. The live webcast will be accessible via the company’s website, with a replay archived for 90 days. Blum is expected to highlight the commercial rollout of MYQORZO (aficamten)—approved in the U.S. and China for obstructive hypertrophic cardiomyopathy—and the recent positive CHMP opinion for EU marketing authorization. He will also discuss late-stage developments in omecamtiv mecarbil for heart failure with reduced ejection fraction and ulacamten for preserved ejection fraction, positioning Cytokinetics for multiple regulatory and commercial milestones in 2026.